Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

Cannabidiol 2Solutions 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Seizures × 90 days × Clear all
NCT05485831 2026-06-03

EpiTALY

Jazz Pharmaceuticals

Active not recruiting
111 enrolled

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05864846 2026-04-27

EpiCom

Jazz Pharmaceuticals

Phase 4 Completed
79 enrolled

Behavior, Seizures, Tuberous Sclerosis

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡